Core Viewpoint - Plus Therapeutics (PSTV) is anticipated to report a year-over-year increase in earnings driven by higher revenues, with a consensus outlook suggesting a quarterly loss of $0.17 per share, reflecting a 77.3% improvement compared to the previous year, and revenues expected to reach $1.85 million, up 10.1% from the same quarter last year [1][3]. Earnings Expectations - The stock may experience upward movement if the reported earnings exceed expectations, while a miss could lead to a decline in stock price [2]. - Management's commentary during the earnings call will significantly influence the sustainability of any immediate price changes and future earnings expectations [2]. Estimate Revisions - The consensus EPS estimate has been revised 31.25% higher in the last 30 days, indicating a collective reassessment by analysts [4]. - A positive Earnings ESP reading is a strong predictor of an earnings beat, especially when combined with a favorable Zacks Rank [8]. Earnings Surprise Prediction - The Most Accurate Estimate for Plus is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -45.46%, suggesting a bearish outlook from analysts [10]. - Despite the negative Earnings ESP, Plus holds a Zacks Rank of 2, complicating predictions regarding an earnings beat [11]. Historical Performance - In the last reported quarter, Plus was expected to post a loss of $0.51 per share but actually reported a loss of $0.67, resulting in a surprise of -31.37% [12]. - The company has not surpassed consensus EPS estimates in any of the last four quarters [13]. Conclusion - Plus does not appear to be a compelling candidate for an earnings beat, and investors should consider additional factors when deciding on their investment strategy ahead of the earnings release [16].
Plus Therapeutics (PSTV) May Report Negative Earnings: Know the Trend Ahead of Q1 Release